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Abstract
Background—Influenza is a major public health problem worldwide; however, relatively little 
is known about influenza in tropical regions, especially for infants. Additional information is 
required to inform public health policy-making, in particular vaccination guidelines.
Methods—Between September 2011 and July 2013, we enrolled newborns into the Nicaraguan 
Birth Cohort Study. Infants were provided primary medical care and actively followed for RT-
PCR-confirmed influenza virus infection when presenting with influenza-like illness or 
undifferentiated fever. This report presents data pertaining to the first year of life.
Results—Of the 518 children enrolled in the study, 441 participated throughout their first year of 
life, 71 were withdrawn, and 6 died. Overall, 13% of the participants experienced at least one 
laboratory-confirmed influenza virus infection. The overall incidence of influenza was 15.5 cases 
per 100 person-years (95% CI: 12.2, 19.5). Infants aged 6–11 months experienced significantly 
higher rates of laboratory-confirmed influenza than infants aged 0–5 months (incidence rate ratio 
2.1, 95% CI: 1.3, 3.4). The overall incidence of pneumonia was 52.6 cases per 100 person-years 
(95% CI: 46.3, 59.6). Three percent of the pneumonia cases were influenza-associated, and the 
incidence of influenza-associated pneumonia and hospitalization was 1.7 (95% CI: 0.9, 3.5) and 
0.22 (95% CI: 0.03, 1.55) cases per 100 person-years, respectively.
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Conclusions—We found a significant burden of influenza and influenza-associated severe 
respiratory outcomes in infants. Our results support the need to explore the potential value of 
vaccinating pregnant women and infants aged >6 months, as recommended by the World Health 
Organization in 2012.
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INTRODUCTION
Influenza is a cause of significant morbidity in children and infants. Infants have the highest 
rates of hospitalization amongst all children1–5; however, data on influenza infection rates in 
the first year of life are relatively limited, especially from developing countries where the 
burden of pneumonia is the highest.6 In 2012, the Strategic Advisory Group of Experts 
(SAGE) on Immunization of the World Health Organization (WHO) updated their position 
on influenza vaccination, identifying pregnant women as the highest priority group and 
children aged 6–23 months as a priority risk group.7 In order to prioritize both the purchase 
and distribution of influenza vaccine, developing countries need more data on the incidence 
of influenza illness in high-risk groups, particularly infants.
In the Americas, influenza vaccination coverage has been rapidly expanded since 2004.8 In 
December 2014, the WHO Technical Burden of Disease Working group established that 
there are insufficient data about the influenza incidence among very young children and that 
more evidence is needed to bolster SAGE recommendations.7 Data on the burden of 
influenza in young children in Latin America are limited. A study we performed in 
Nicaraguan children aged 2–14 years showed high attack rates for pandemic H1N1 
influenza as well as seasonal influenza A and B.9 A study in Guatemala identified children 
aged 6 months to 5 years as a priority group for vaccination for pandemic influenza in 
2009.10 A study in El Salvador found on average 3.2 influenza-associated severe pneumonia 
cases per 1,000 person-years in children >5 years of age over multiple influenza seasons.11 
Thus, data are needed on influenza particularly in infants <12 months of age.
In 2011, we established the Nicaraguan Influenza Birth Cohort Study to characterize the 
burden of influenza in children aged 0 to 2 years in Managua, Nicaragua, to examine the risk 
factors for influenza virus infection and disease severity and to investigate sequential 




This study was conducted in collaboration between the Sustainable Sciences Institute, the 
Nicaraguan Ministry of Health, the University of California, Berkeley (UCB), the University 
of Michigan, Ann Arbor (UM), and the US Centers for Disease Control and Prevention 
(CDC). The study was approved by the Institutional Review Boards (IRBs) of the 
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Nicaraguan Ministry of Health, UM, and UCB. The CDC’s IRB relied on the UCB IRB for 
approval. Written informed consent was obtained from a parent/guardian of all participants.
Study site and population
The Nicaraguan Influenza Birth Cohort Study is an ongoing prospective cohort study based 
at the Health Center Socrates Flores Vivas (HCSFV), a primary health care facility run by 
the Nicaraguan Ministry of Health. The HCSFV serves a population of approximately 
61,500, in the low-to-middle income District II of the city of Managua. For inclusion in the 
study, a participant must (1) have been ≤4 weeks of age at enrollment, (2) lived in the 
HCSFV catchment area, (3) had no plan to leave the study area in the next 2 years, and (4) 
have been willing to attend the HCSFV for all medical needs. Infants with 
immunocompromising conditions and premature infants who required ≥4 weeks of 
hospitalized care directly following birth were excluded. Infants were recruited when 
parents/guardians brought them to their first well-baby appointment or through house visits. 
Participants were enrolled in the study until the age of 2 years, unless they voluntarily 
withdrawn before reaching that age. Recruitment into the study began in September 2011. 
Every month, approximately 20–24 children were enrolled.
Enrollment, medical care and annual surveys
At enrollment, socio-economic, risk factor, and breastfeeding questionnaires were 
administered by study personnel. Participants’ health status was followed through parent 
self-reporting on a standardized symptom diary and medical visits at the HCSFV. Parents/
guardians were instructed to fill out a simple daily symptom diary for the infant collecting 
information on the presence of fever, cough, and runny nose. Diaries were collected weekly 
from the participant’s home by a study field worker who was instructed to refer participants 
with current symptoms to the HCSFV. Parents/guardians were encouraged to seek medical 
care for all participant illnesses at the HCSFV and to present early in case of a febrile 
illness. Infants were identified as study participants at chart reception and routed to the study 
area of the HCSFV. Study physicians were available to all participants 24 hours/day, 7 days/
week, and information pertaining to clinical visits was systematically recorded on a 
standardized case report form. Children requiring hospitalization were transferred to a 
hospital by study staff.
Every year in March/April, length and weight of healthy infants were measured and 
questionnaires completed at enrollment were re-administered by study staff to examine risk 
factors for influenza virus infection and outcome. A blood sample of 3 ml was collected 
from infants aged 6 months or older in March/April and banked for future analysis.
Respiratory sampling and case follow-up
Respiratory samples were collected from children presenting with 1) influenza-like illness 
(ILI), defined as fever (≥37.8°C) or history of fever, and rhinorrhea and/or cough;12 2) fever 
or history of fever without a defined focus; or 3) severe respiratory symptoms (stridor, nasal 
flaring, wheezing, chest indrawing, and/or central cyanosis) regardless of the presence of 
fever. Participants identified >96 hours after symptom onset were not sampled. Study staff 
obtained oropharyngeal swabs from infants <6 months as this is the least invasive sampling 
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method. Combined nasal and oropharyngeal swabs were obtained from older infants. After 
sample collection and depending on the severity of the illness, participants were asked to 
return to the HCSFV for at least one follow-up visit. Daily occurrence of fever and 
respiratory symptoms, as observed by the physician or as reported by the parent, were 
recorded in a separate form. Pneumonia and severe pneumonia were clinically assessed 
using the WHO’s Integrated Management of Childhood Illnesses (IMCI) guidelines.13
Influenza virus detection
Swab specimens were placed in viral transport media, stored at 4°C, and transported within 
72 hours to the National Virology Laboratory at the National Center for Diagnosis and 
Reference (CNDR) of the Nicaraguan Ministry of Health. RNA was extracted (QIAamp 
Viral RNA Mini Kit, Qiagen) and tested by real-time reverse-transcription polymerase chain 
reaction (RT-PCR) for influenza A and B using primers, probes and protocols supplied by 
the CDC. Samples positive for influenza A, were subtyped for seasonal influenza A 
H1N1pmd09 and H3N2, and lineage-specific PCR for both influenza B Victoria and 
Yamagata were run for influenza B positive samples.14
Statistical analysis
Follow-up time was calculated as the time between enrollment and the infant’s first birthday 
or withdrawal from the study. For those lost to follow-up, person-years were calculated as 
the time between enrollment and last contact with study personnel, plus one-half the time 
between the last contact and the date recorded as lost to follow-up. A Poisson distribution 
was used to calculate 95% confidence intervals (CIs) for incidence rates. Incidence rate 
ratios (IRRs) were calculated using generalized estimating equations (GEE) with a Poisson 
distribution and robust standard errors. Statistical analyses were performed in STATA 13 
(StataCorp LP).
RESULTS
The Nicaraguan Influenza Birth Cohort Study
Enrollment began on September 8, 2011 and continued through July 15, 2013 with 
approximately 20 newborns, aged 4 weeks or less, enrolled monthly. Most (97%) of the 
parents/guardians invited to participate in the study agreed to enroll their children.
This report focuses on the first year of life. All infants born on or before July 15, 2013 were 
included in this analysis (n=518). A total of 441 (85%) infants, were followed until their first 
birthday, while 77 (15%) were withdrawn. Forty-six families moved outside of the study 
area and were lost-to-follow-up. Six infants died while enrolled in the study, 5 with severe 
pneumonia, which was accompanied with heart and/or lung congenital malformations in two 
of the five deaths. On average, the time of participation in the study was 0.9 years (10.5 
months) per child. Fifty-eight (11%) women were vaccinated against influenza during 
pregnancy (Table 1). A total of 23 (4%) children were vaccinated between 6 months and 1 
year of age.
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A total of 23,654 symptom diaries from 517 (99.8%) of the 518 study infants were collected 
by field workers, with most (96%) collected in the week following their completion. The 
average number of medical visits per participant was 13 (range: 0–50), and 504 (97%) 
participants attended at least one medical visit. The total number of medical visits attended 
was 6,552 with 4,577 (70%) initial visits (i.e., medical visits for a new illness) and 1,975 
(30%) follow-up visits.
Influenza-like illness and respiratory sample collection
A total of 1,286 influenza-like illnesses (ILI) were identified using the symptoms diaries 
completed by the parent/guardians of study participants and 1,053 ILI events were 
medically-attended. Three hundred and ninety-eight (77%) participants experienced at least 
one medically-attended ILI event. The average number of medically-attended ILI events per 
infant was 2.0 (range: 0–12). The incidence of medically-attended ILI was 229.6 cases per 
100 person-years and was similar in both genders (Table 2). The medically-attended ILI 
incidence was higher in infants aged ≥6 months when compared to younger infants (Table 
2). Of the 1,053 medically-attended ILI cases, 1,021 presented in the first 96 hours from 
symptom onset and thus met the testing definition. Of these, 1,019 (99.8%) had a respiratory 
sample collected immediately after presentation. Moreover, an additional 165 samples were 
collected from infants presenting with fever without a defined focus and 29 from infants 
with severe respiratory symptoms in the absence of fever.
Incidence of influenza
Of the 1,213 collected samples, 74 (6%) tested positive for influenza by RT-PCR. Three 
infants had two respiratory samples that tested positive for the same influenza virus type/
subtype within 14 days, and were considered a single influenza infection, leaving a total of 
71 influenza positive cases. Of the 518 infants, 68 (13%) tested positive at least once, 3 
children experienced two infections. Of the influenza cases (n=71), 49 were attributed to 
influenza A and 22 to influenza B. Of the 49 influenza A cases, 12 were H1N1pdm09 and 
37 were H3N2. All influenza B cases tested were positive for the Victoria lineage. Influenza 
occurred predominantly during June–November in 2012 and June–October in 2013 (Figure 
1).
Seven (10%) influenza cases did not meet the ILI definition and presented with fever 
without a defined focus. No infant with severe respiratory symptoms in the absence of fever 
tested positive for influenza. Three (0.6%) participants experienced two influenza infections 
during their first year of life. Two participants exhibited two influenza A infections (in both 
cases, one H1N1pdm09 and one H3N2), and one experienced an influenza A H1N1pdm09 
infection and an influenza B infection. The mean number of days between infections was 49 
(range: 24–268).
The incidence of laboratory-confirmed influenza illness among children meeting the testing 
definition was 15.5 cases per 100 person-years (95% CI: 12.2, 19.5) (Table 2). Consistent 
with the ILI data, influenza incidence was higher in children aged 6 months or older. This 
increased incidence in infants aged 6 months or older compared to younger infants was 
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significant for both influenza A (IRR: 1.87, 95% CI: 1.04, 3.37) and influenza B (IRR: 2.65, 
95% CI: 1.04, 6.78).
Clinical presentation of ILI and influenza
We then compared influenza-positive and -negative cases in terms of clinical signs at 
presentation. For this analysis, participants who were sampled because they presented with 
severe respiratory symptoms in the absence of fever were excluded (n=29). The proportion 
of children who presented with rhinorrhea and nasal congestion was significantly higher in 
influenza-positive cases (Table 3). On the contrary, the proportion of children with cough, 
increased respiratory rate, difficult breathing, or loss of appetite was not different in 
influenza-positive versus influenza-negative cases (Table 3). Clinical symptoms throughout 
the episodes were also compared using the daily information collected during the initial and 
follow-up medical consults in the follow-up forms. Follow-up consults were attended by 763 
(63%) of the participants who were sampled. The number of days with clinical symptoms 
was not different in influenza-positive versus influenza-negative cases (See Table, 
Supplemental Digital Content 1).
Severe manifestations of influenza virus infection
We examined the contribution of influenza virus infection to severe respiratory outcomes. A 
total of 241 pneumonia cases were identified in the study, yielding an incidence of 52.6 
cases per 100 person-years (95% CI: 46.3, 59.6). Eight (3%) had a positive influenza test at 
presentation or in the 28 days prior to onset of pneumonia and were considered influenza-
associated. These 8 influenza-associated pneumonia cases were distributed as follows: 4 
presented with an initial diagnosis of pneumonia and were influenza-positive at presentation 
(time between symptom onset and presentation: 1 day for all 4 cases); 2 presented with ILI, 
tested positive for influenza, and developed pneumonia during follow-up (time between ILI 
and pneumonia onset for both cases: 3 days); and 2 presented with ILI, tested positive for 
influenza, and developed pneumonia after the initial illness resolved (time between ILI and 
pneumonia onset: 16 and 18 days). Further, 1/60 (1.7%) severe pneumonia and 1/81 (1.2%) 
hospitalizations for respiratory causes were influenza-associated. The influenza-associated 
hospitalization was due to severe pneumonia. The incidence of influenza-associated 
pneumonia and hospitalization was 1.7 (95% CI: 0.9, 3.5) and 0.22 (95% CI: 0.03, 1.55) 
cases per 100 person-years, respectively (Table 2). None of the 6 infants who died during 
the course of the study had an influenza infection in the month before their death.
DISCUSSION
We actively followed a cohort of infants through their first birthday in order to ascertain 
clinical influenza infection rates. Infants in our cohort had a substantive risk of developing 
influenza illness: 13% experienced one or more laboratory-confirmed influenza illnesses. 
One in 65 also developed laboratory-confirmed influenza illness associated with pneumonia. 
In our study, infants aged 6 months and older had a higher incidence of both influenza A and 
B, than younger children.
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The incidence of laboratory-confirmed influenza among children with ILI or fever without a 
defined focus seeking care in our study (i.e., 15.5 cases per 100 person-years (95% CI: 12.2, 
19.5) is similar to or higher than what has been found in other studies both within the region 
and worldwide. A study of influenza illness among infants in Bangladesh found a rate of 
10.2 influenza infections per 100 person-year through community-based surveillance of 
children <5 years.15 A second study in Bangladesh observed 6 (95% CI: 3, 12) and 20 (95% 
CI: 14, 28) influenza illnesses per 100 person-years in children under 6 months of age and 
infants aged 6 to 12 months, respectively.16 In the US, rates of medically attended influenza 
illness in infants have ranged from 2.8 (95% CI: 0.7, 11.1) to 5.9 (95% CI: 2.8, 12.8) cases 
per 100 person-years in infants <6 months, and from 5.2 (95% CI: 3.0, 9.0) to 12.5 (95% CI: 
8.7, 17.9) cases per 100 person-years in children aged 6 to 23 months.17 In the placebo arm 
of a randomized-controlled trial in Bangladesh, an incidence of 22.1 influenza cases per 100 
person-years (95% CI: 13.5, 36.0) was observed in infants between 0 and 24 weeks of age.18 
In a similar study in South Africa, an influenza attack rate of 3.6% (95% CI: 2.6, 5.0) was 
calculated in the same age group.19 Differences in influenza rates may be due to differences 
in case-definitions, respiratory sampling algorithms, laboratory assays among other study 
design issues, as well as yearly variation in influenza virus circulation and transmission.
Importantly, 3% of clinical pneumonia cases in our study, as defined by IMCI guidelines 13, 
were attributable to influenza infection. Lower proportions of severe pneumonia (1.7%) and 
hospitalization for respiratory causes (1.2%) were attributable to influenza infection, and we 
did not document any influenza-associated deaths. Overall, our rate of influenza-associated 
hospitalizations (0.22 per 100 person-years; 95% CI: 0.03, 1.55) was similar to other studies 
of children aged 5 years and under, e.g., 0.12 in Oregon20; 0.12 in Kiel, Germany21; and 
0.09 (95% CI: 0.08, 0.11) in 3 counties in the United States.17 To estimate the actual burden 
of influenza-associated hospitalizations, our study was based in the community and tested 
infants for influenza virus infections before hospitalization, which should result in a more 
accurate estimate of the hospitalization rates than studies of hospitalized influenza which 
typically test for influenza after the child has been hospitalized and may no longer be 
shedding influenza virus. Also, our study was restricted to infants, who are at higher risk for 
influenza-associated hospitalization. In fact, a study reported influenza-associated estimated 
excess rates of hospitalization during periods of influenza circulation to be 1.34 (95% CI: 
0.88, 1.80) and 1.03 (95% CI: 0.47, 1.58) in California and Seattle, respectively.22 Finally, 
regional differences probably contributed to the observed differential risk of influenza-
associated hospitalization.23,24
Since 2012, the Strategic Advisory Group of Experts (SAGE) on Immunization of the WHO 
has recommended that pregnant women be the top priority group and that young children be 
a priority for influenza vaccination in the community.7 In Nicaragua, pregnant women and 
children aged 6–23 months are prioritized during vaccination campaigns. We found that 
approximately one in ten pregnant women in our study population were vaccinated against 
influenza during their pregnancy. Infant vaccination rates were particularly low in our study 
population with only one infant in 20 receiving the influenza vaccine. These low vaccination 
rates could be due to the limited availability of the vaccine in the country. More research is 
needed on the cost effectiveness of the vaccination among pregnant women and in young 
infants to inform vaccination policy.
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One limitation of our study is that it was conducted in a single location over two years. 
Influenza incidence is known to vary by year and location, so longer-term follow-up in 
several locations is ideal. Additionally, differences in our age-specific respiratory sampling 
protocol (i.e., oropharyngeal swab only in infants under 6 months) may have contributed to 
the difference in incidence observed between the two age groups. However, other studies 
without differences in sample type have found similar results.16,17 Lastly, we limited testing 
to 96 hours post symptom onset, as some infants do shed virus for longer, we may have 
underestimated the true incidence.
Strengths of our study include active surveillance of infants, high study acceptance in the 
community, high compliance with study procedures, and a broad testing definition, which 
includes not only ILI but also fever without a defined focus and afebrile cases with severe 
respiratory disease. Importantly, 10% of the influenza virus infections detected in the study 
occurred in infants presenting with fever without a defined focus, showing a clear benefit of 
our testing strategy to enable more complete estimates of influenza incidence. However, our 
testing definition did not include afebrile infants presenting with mild respiratory symptoms.
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Figure. Incidence of influenza-like illness and influenza by study month
Monthly incidence of influenza-like illness (ILI) and laboratory-confirmed influenza.
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Table 1
Characteristics of study participants at enrollment
n = 518
Age at enrollment, no. (%)
 0–2 weeks 362 (70)
 3–4 weeks 156 (30)
Male sex, no. (%) 253 (49)
Infants vaccinated against influenza, no. (%)* 23 (4)
Mothers vaccinated against influenza during pregnancy, no. (%)* 58 (11)†
No. of persons in household, mean (SD) 9.5 (5)
Secondary tobacco exposure, no. (%) 198 (38)
Mothers with secondary or tertiary education, no. (%) 415 (80)‡
Fathers with secondary or tertiary education, no. (%) 394 (76)‡
*
Vaccination status was assessed through interviews and review of the vaccination card, medical record, and Health Center’s vaccination logs.
†
Fifty-nine mothers with vaccination status unknown.
‡
Two missing data (n=516).
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Table 2
Incidence of influenza-like illness, laboratory-confirmed influenza and influenza-associated pneumonia*
Influenza-like illness Laboratory-confirmed influenza Influenza-associated pneumonia
Overall 229.6 (216.1, 243.9) 15.5 (12.2, 19.5) 1.7 (0.9, 3.5)
By Sex
Male 220.1 (201.5, 240.4) 15.6 (11.2, 21.7) 1.8 (0.7, 4.8)
Female 238.7 (219.7, 259.3) 15.4 (11.1, 21.3) 1.7 (0.6, 4.6)
Incidence rate ratio
Male ref. ref. ref.
Female 1.09 (0.93, 1.28) 0.98 (0.63, 1.54) 0.95 (0.24, 3.79)
By Age
0 – 5 months 173.4 (157.2, 191.4) 10.1 (6.7, 15.1) 0.87 (0.22, 3.49)
6 – 12 months 285.6 (264.5, 308.3) 20.9 (15.7, 27.7) 2.6 (1.2, 5.8)
Incidence rate ratio
0 – 5 months ref. ref. ref.
6 – 12 months 1.63 (1.44, 1.85)† 2.08 (1.26, 3.41)† 2.99 (0.60, 14.82)
*
Incidence data are presented as cases per 100 person-years (95% confidence interval).
†
Estimates in bold are statistically significant.
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Table 3
Symptoms at presentation in influenza-positive vs. influenza-negative cases*
Influenza
Positive n = 71 Negative n = 1,110 p-value
Cough, no. (%) 52 (73) 794 (72) 0.756†
Rhinorrhea, no. (%) 61 (86) 804 (72) 0.012†
Nasal congestion, no. (%) 39 (55) 471 (42)‡ 0.039†
Loss of appetite, no. (%) 14 (20) 206 (19) 0.807†
Increased respiratory rate, no. (%) 2 (3) 68 (6) 0.252†
Difficult breathing, no. (%) 1 (1) 19 (2) 0.849†
Age ≥6 months, no. (%) 48 (68) 671 (60) 0.230†
Day of presentation, mean (SD) 1.8 (0.9) 1.8 (1.3) 0.949§
*




Five missing data (n=1,078).
§
Independent two-sample t-test.
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